Product image of Imbruvica (Ibrutinib) supplied by GNH India

Imbruvica

Active Ingredient:
Ibrutinib
Origin:
EU

Imbruvica (Ibrutinib)

Ibrutinib, the active ingredient in Imbruvica, is a Bruton’s tyrosine kinase (BTK) inhibitor presented as a capsule for oral use. It is employed in the treatment of several B‑cell malignancies and related immune disorders. GNH India supplies Imbruvica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Janssen-Cilag International Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imbruvica (ibrutinib) targets B‑cell receptor signaling and is indicated for several B‑cell malignancies.

  • Chronic lymphocytic leukemia (CLL): improves disease control and prolongs progression‑free survival in adult patients.
  • Mantle cell lymphoma (MCL): induces tumor regression in relapsed or refractory disease.
  • Waldenström macroglobulinemia: reduces IgM levels and disease activity.
  • Marginal zone lymphoma: provides disease control in adult patients.
  • Chronic graft‑versus‑host disease (cGVHD): alleviates symptoms in steroid‑refractory adult patients.

How It Works

  • Ibrutinib irreversibly binds to the active site of Bruton's tyrosine kinase, a key enzyme in B‑cell receptor signaling. By blocking BTK, the drug disrupts downstream pathways that promote malignant B‑cell survival, proliferation, and migration, leading to apoptosis of cancerous cells and modulation of immune responses.

Side Effects

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects

  • Diarrhea: loose stools occurring during therapy.
  • Bleeding: increased tendency to bruise or bleed.
  • Atrial fibrillation: irregular heart rhythm episodes.
  • Nausea: feeling of sickness or urge to vomit.
  • Rash: skin irritation or redness.
  • Fatigue: persistent tiredness.

Serious or Rare Side Effects

  • Severe infections: opportunistic or life‑threatening bacterial, fungal, or viral infections.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Secondary malignancies: emergence of new cancers.
  • Major hemorrhage: gastrointestinal or intracranial bleeding.
  • Cardiac arrhythmias: serious rhythm disturbances beyond atrial fibrillation.

Precautions & Warnings

Before initiating Imbruvica, clinicians should assess several safety parameters.

  • Monitor blood counts: perform regular complete blood count tests.
  • Assess bleeding risk: evaluate concurrent anticoagulant or antiplatelet use.
  • Screen cardiac history: watch for atrial fibrillation or other arrhythmias.
  • Evaluate liver function: conduct periodic liver enzyme assessments.
  • Counsel on infection signs: advise prompt reporting of fever or unexplained illness.
  • Store at ambient temperature: keep below 25°C, protect from moisture and keep in original packaging.

Avoid Interactions

Imbruvica may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Anticoagulants (warfarin, DOACs): heightened bleeding risk.
  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): increased ibrutinib exposure.
  • Strong CYP3A4 inducers (rifampin, phenytoin): reduced drug efficacy.
  • Antifungal azoles (itraconazole, posaconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (fluconazole, erythromycin): may modestly increase exposure.
  • Moderate CYP3A4 inducers (carbamazepine, phenobarbital): may modestly decrease exposure.
  • CYP2C8 substrates (paclitaxel): potential altered metabolism.
  • Live vaccines: possible reduced vaccine efficacy.

Frequently Asked Questions

Imbruvica (ibrutinib) is approved for several B‑cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, and for chronic graft‑versus‑host disease that is refractory to steroids.

Ibrutinib binds irreversibly to Bruton's tyrosine kinase, a pivotal enzyme in B‑cell receptor signaling. This blockade stops downstream survival signals, leading to apoptosis of malignant B‑cells and modulation of immune activity.

The dose of Imbruvica is individualized by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and any concomitant medications. No universal dosing schedule is provided here.

Imbruvica is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy.

To request Imbruvica, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imbruvica is a first‑generation BTK inhibitor with a well‑characterized safety profile. Newer BTK inhibitors may offer different dosing schedules or selectivity, while alternative classes such as BCL‑2 inhibitors or monoclonal antibodies target distinct pathways. Choice depends on disease characteristics, prior therapy, and patient tolerance.

Imbruvica capsules should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Do not store in bathrooms or near heat sources.

Imbruvica is taken orally as a capsule with water, usually once daily. Patients should follow the prescriber’s instructions regarding food intake, as the drug can be taken with or without meals.

Serious risks include severe infections, bleeding events, atrial fibrillation or other cardiac arrhythmias, tumor lysis syndrome, hepatotoxicity, and the possible development of secondary cancers. Patients should report any unusual symptoms promptly.

Imbruvica is contraindicated in patients with known hypersensitivity to ibrutinib or any capsule components. Caution is advised for individuals with uncontrolled bleeding disorders, severe hepatic impairment, or active uncontrolled infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibrutinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT